Market Place
Sourcing Support
Merck acquires VelosBio: exploring the promise of ROR1 in cancer
19 Nov 2020 //
PHARMACEUTICAL TECHNOLOGY
Merck to bolster cancer drug portfolio with VelosBio $2.75 billion deal
06 Nov 2020 //
REUTERS
VelosBio doses first patient in Phase II solid tumour drug trial
19 Oct 2020 //
BIOSPACE
VelosBio gets FDA Designations for VLS-101 in Patients with Mantle Cell Lymphoma
31 Aug 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.